Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487.

2.

Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.

Buvat J, Hatzichristou D, Boess FG, Büttner H, Gehchan N, Henneges C, Porst H.

Int J Clin Pract. 2014 Sep;68(9):1087-99. doi: 10.1111/ijcp.12449. Epub 2014 Aug 14.

PMID:
25123817
3.

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

Ziegler D, Schneider E, Boess FG, Berggren L, Birklein F.

J Diabetes Complications. 2014 Sep-Oct;28(5):698-704. doi: 10.1016/j.jdiacomp.2014.04.004. Epub 2014 Apr 18.

PMID:
24862108
4.

Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.

Hatzimouratidis K, Buvat J, Büttner H, Vendeira PA, Moncada I, Boehmer M, Henneges C, Boess FG.

Int J Impot Res. 2014 Nov-Dec;26(6):223-9. doi: 10.1038/ijir.2014.15. Epub 2014 May 1.

PMID:
24784894
5.

Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.

Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, Ziegler D.

Clin J Pain. 2014 Oct;30(10):875-85. doi: 10.1097/AJP.0000000000000057.

PMID:
24296910
6.

Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.

Buvat J, Büttner H, Hatzimouratidis K, Vendeira PA, Moncada I, Boehmer M, Henneges C, Boess FG.

J Sex Med. 2013 Jun;10(6):1592-602. doi: 10.1111/jsm.12130. Epub 2013 Apr 2.

PMID:
23551622
7.

Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Boess FG, de Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, König G.

Psychopharmacology (Berl). 2013 May;227(1):1-17. doi: 10.1007/s00213-012-2933-4. Epub 2012 Dec 16.

PMID:
23241647
8.

Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?

Wilhelm S, Boess FG, Hegerl U, Mergl R, Linden M, Schacht A, Schneider E.

Expert Opin Drug Saf. 2012 Sep;11(5):699-711. doi: 10.1517/14740338.2012.699521. Epub 2012 Jun 20.

PMID:
22712514
9.

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.

Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G.

Neuropharmacology. 2012 Feb;62(2):1099-110. doi: 10.1016/j.neuropharm.2011.10.024. Epub 2011 Nov 10.

PMID:
22085888
10.

Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Lakics V, Karran EH, Boess FG.

Neuropharmacology. 2010 Nov;59(6):367-74. doi: 10.1016/j.neuropharm.2010.05.004. Epub 2010 May 21. Erratum in: Neuropharmacology. 2013 Apr;67:532.

PMID:
20493887
11.

The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.

Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.

J Pharmacol Exp Ther. 2007 May;321(2):716-25. Epub 2007 Feb 16.

PMID:
17308038
12.

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G.

Neuropharmacology. 2004 Dec;47(7):1081-92.

PMID:
15555642
13.

Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine(3A) receptor.

Steward LJ, Boess FG, Steele JA, Liu D, Wong N, Martin IL.

Mol Pharmacol. 2000 Jun;57(6):1249-55.

PMID:
10825397
14.

Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N, Sleight AJ.

Br J Pharmacol. 1999 Apr;126(7):1537-42.

15.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
16.

Comparison of native 5-HT3 receptors purified from various neuroblastoma-derived cell lines and bovine brain with recombinant 5-HT3-AL receptors purified after expression in HEK293 cells.

Boess FG, Creighton RM, Phipps BA, McKernan RM, Reid J, Martin IL.

Ann N Y Acad Sci. 1998 Dec 15;861:276-7. No abstract available.

PMID:
9928288
17.

The putative 5-ht6 receptor: localization and function.

Sleight AJ, Boess FG, Bös M, Bourson A.

Ann N Y Acad Sci. 1998 Dec 15;861:91-6. Review.

PMID:
9928244
18.

Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

Bourson A, Boess FG, Bös M, Sleight AJ.

Br J Pharmacol. 1998 Dec;125(7):1562-6.

20.

The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.

Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ.

Mol Pharmacol. 1998 Sep;54(3):577-83.

PMID:
9730917
21.

Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.

Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A.

Br J Pharmacol. 1998 Jun;124(3):556-62.

22.

Correlation between 5-HT7 receptor affinity and protection against sound-induced seizures in DBA/2J mice.

Bourson A, Kapps V, Zwingelstein C, Rudler A, Boess FG, Sleight AJ.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):820-6.

PMID:
9453469
23.

Interaction of tryptamine and ergoline compounds with threonine 196 in the ligand binding site of the 5-hydroxytryptamine6 receptor.

Boess FG, Monsma FJ Jr, Meyer V, Zwingelstein C, Sleight AJ.

Mol Pharmacol. 1997 Sep;52(3):515-23.

PMID:
9284367
24.

Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.

Boess FG, Monsma FJ Jr, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ.

Neuropharmacology. 1997 Apr-May;36(4-5):713-20.

PMID:
9225298
25.

Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: importance of glutamate 106.

Boess FG, Steward LJ, Steele JA, Liu D, Reid J, Glencorse TA, Martin IL.

Neuropharmacology. 1997 Apr-May;36(4-5):637-47.

PMID:
9225289
26.

Ultrastructure of the 5-hydroxytryptamine3 receptor.

Boess FG, Beroukhim R, Martin IL.

J Neurochem. 1995 Mar;64(3):1401-5.

PMID:
7861173
27.

Molecular biology of 5-HT receptors.

Boess FG, Martin IL.

Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317. Review. No abstract available.

PMID:
7984267
28.

Molecular properties of 5-hydroxytryptamine3 receptor-type binding sites purified from NG108-15 cells.

Boess FG, Lummis SC, Martin IL.

J Neurochem. 1992 Nov;59(5):1692-701.

PMID:
1402914
29.

5-HT3 receptors in NG108-15 neuroblastoma x glioma cells: effect of the novel agonist 1-(m-chlorophenyl)-biguanide.

Boess FG, Sepúlveda MI, Lummis SC, Martin IL.

Neuropharmacology. 1992 Jun;31(6):561-4.

PMID:
1407396
30.

Purification and characterization of 5-HT3 receptors from NG108-15 neuroblastoma x glioma cells.

Boess FG, Martin IL.

Biochem Soc Trans. 1992 May;20(2):217S. No abstract available.

PMID:
1397590
31.

Supplemental Content

Loading ...
Support Center